Kelzy (Dienogest, Ethinylestradiol | Lactose)

The combination contains dienogest, a synthetic progestogen, and ethinylestradiol, an estrogen. Ethinylestradiol suppresses the luteinising hormone surge, while dienogest reinforces this suppression, blocks ovulation, thickens cervical mucus and alters the endometrium, making fertilisation and implantation unlikely.

The dosing regimen for Kelzy is determined by the prescribing clinician. Typically, a combined oral contraceptive is taken once daily for 21 consecutive days followed by a 7‑day hormone‑free interval, but the exact schedule should be confirmed with the prescriber.

Kelzy is contraindicated in pregnancy and should not be started or continued by women who are pregnant. While limited data exist for breastfeeding, most guidelines advise against using combined estrogen‑progestogen contraceptives during lactation because of potential effects on milk production and infant exposure.

To order Kelzy, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Kelzy contains dienogest as the progestogen, which offers a slightly different side‑effect profile compared with older progestins such as levonorgestrel. Efficacy in preventing pregnancy is comparable across approved combined oral contraceptives, but the choice may depend on individual tolerance, acne benefits, and specific cardiovascular risk considerations.

Kelzy tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and ensure they are out of reach of children.

Kelzy is taken orally as a tablet. The recommended practice is to swallow one tablet each day at the same time, with or without food, for the prescribed cycle length. Missing a dose should be managed according to the prescribing information.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial clot events such as stroke or myocardial infarction, severe hypertension, and liver dysfunction. Patients should seek immediate medical attention if they experience unexplained chest pain, severe headache, visual changes, or sudden swelling of the legs.

Kelzy should not be used by women who are pregnant, have a known or suspected thromboembolic disorder, uncontrolled hypertension, active liver disease, breast cancer, or estrogen‑dependent tumors. It is also contraindicated in smokers over 35 years of age and in individuals with known hypersensitivity to any component of the tablet.